BindingDB logo
myBDB logout

72 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26709102 142 Discovery of Vibegron: A Potent and Selective▀3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.EBI Merck Research Laboratories
26125514 40 Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human▀3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.EBI Asahi Kasei Pharma Corporation
16759089 5 Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.EBI The University of Melbourne
11311067 38 Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.EBI Kissei Pharmaceutical Company Ltd.
2884312 39 Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.EBI TBA
17845020 44 Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.EBI Universit£ degli Studi di Torino
15482914 25 Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750.EBI Pfizer Inc.
12502364 17 Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.EBI Kissei Pharmaceutical Company Ltd.
7562902 114 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.EBI SmithKline Beecham Pharmaceuticals
8254623 20 Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.EBI National Institute of Diabetes and Digestive and Kidney Diseases
8230093 21 Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.EBI Universit£ di Pisa
1313109 20 Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.EBI Universit£ di Pisa
21783363 10 Synthesis and in vitro evaluation of derivatives of theß¿?-adrenergic receptor antagonist HX-CH 44.EBI University of Toronto
20036561 39 Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.EBI Medical University of Lublin
21277205 26 Discovery of substituted phenyl urea derivatives as novel long-actingß2-adrenoreceptor agonists.EBI Rhône-Poulenc Rorer
20812727 157 Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.EBI National Institute of Mental Health
19131251 9 Preliminary evaluation of pharmacological properties of some xanthone derivatives.EBI Jagiellonian University Medical College
18599160 4 Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1.EBI Rzeszów University of Technology
17911024 37 Potent oxindole based human beta3 adrenergic receptor agonists.EBI Lilly Research Laboratories
17632003 55 Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.EBI Pfizer Global Research and Development
17506540 52 Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.EBI Medical University of Lublin
16931005 21 Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.EBI Lilly Research Laboratories
16722631 87 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.EBI Predix Pharmaceuticals Ltd.
10780918 27 Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (S)-2- and 6-fluoroepinephrine: effect of stereochemistry on fluorine-induced adrenergic selectivities.EBI National Institute of Diabetes and Digestive and Kidney Diseases
10743949 32 (1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents.EBI Università di Perugia
9876110 58 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).EBI Centro de Investigación Grupo Ferrer
9572886 38 Synthesis and adrenergic activity of a new series of N-aryl dicyclopropyl ketone oxime ethers: SAR and stereochemical aspects.EBI University of Grenoble
7910217 36 The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists.EBI Universitá di Pisa
2892936 10 Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.EBI Warner-Lambert Company
2875184 11 (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.EBI TBA
1672155 11 Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.EBI National Institute of Diabetes
1652023 161 Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.EBI Abbott Laboratories
1354264 16 Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.EBI American Cyanamid Company
16915381 31 WAY-100635 is a potent dopamine D4 receptor agonist.BDB Purdue University
16352709 44 Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.BDB McGill University
15999145 62 Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.BDB Case Western Reserve University
15831442 46 Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.BDB Taisho Pharmaceutical Co., Ltd
12761331 97 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.BDB Case Western Reserve University
12721338 61 N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.BDB Pudue Pharma Discovery Research
12649361 779 L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.BDB Case Western Reserve University
12431845 85 Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.BDB Lilly Research Laboratories
12192085 52 Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.BDB Case Western Reserve University
12110997 380 In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.BDB Westfälische Wilhelms-Universitä Muenster,
11750180 141 Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.BDB Lilly Research Laboratories
11082453 77 ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.BDB Abbott Laboratories
10379421 134 Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.BDB TBA
9395253 17 Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.BDB Eli Lilly and Co.
9336327 37 The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.BDB Preclinical R & D, Astra Arcus AB
9225287 174 RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.BDB Roche Bioscience
8996185 121 Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.BDB Synthélabo Recherche
8788493 64 Novel discriminatory ligands for 5-HT2B receptors.BDB SmithKline Beecham Pharmaceuticals
8584042 40 BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.BDB Boehringer Ingelheim Italia
8564266 77 Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.BDB Vrije Universiteit
8564196 35 Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo.BDB Syntex Discovery Research
8386236 11 In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist.BDB Whitby Research, Inc.
8093723 20 Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.BDB Dainippon Pharmaceutical Co., Ltd.
8012715 38 GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor.BDB Glaxo Group Research Ltd.
7910212 34 Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.BDB Yamanouchi Pharmaceutical Co. Ltd.
7523657 14 Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity.BDB Eli Lilly and Company
3790168 23 Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.BDB Wyeth Laboratories, Inc.
2869639 166 Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.BDB Astra Läkemedel AB
2583244 35 Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study.BDB Virginia Commonwealth University
2530094 94 The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.BDB Novo Industri A/S
1982626 30 Neurochemical profile of eltoprazine.BDB Duphar B.V.
1968985 56 Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.BDB Niigata College of Pharmacy
1661335 95 Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins.BDB Center for Bio-Pharmaceutical Sciences
1352553 39 Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.BDB University of North Carolina